CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise President and CEO acquired 1,118 shares (option exercise)
- 4 Open-market buy 10% owner bought 312,500 shares at $16.00 ($5,000,000)
- 4 Conversion Chief Financial Officer acquired 26,187 shares (conversion)
- 4 Open-market buy Director bought 35,000 shares at $16.00 ($560,000)
- 4 Shares withheld for taxes President and CEO gave up 10 shares (to pay taxes)
- 4 Open-market buy 10% owner bought 312,500 shares at $16.00 ($5,000,000)
- 4 Open-market buy 10% owner bought 750,000 shares at $16.00 ($12,000,000)
- 4 Open-market buy Director bought 6,250 shares at $16.00 ($100,000)
- 3/A Insider 3/A
Page 6 of 7 · 140 filings